Information Provided By:
Fly News Breaks for June 27, 2016
GWPH
Jun 27, 2016 | 10:17 EDT
Leerink analyst Paul Matteis raised his price target for GW Pharmaceuticals to $138 after the company announced positive results for its first Phase 3 study for Epidiolex in Lennox-Gastaut Syndrome. The analyst now sees an 85% probability-of-success in LGS and a 90% probability of approval in Dravet. Matteis reiterates an Outperform rating on shares of GW.
News For GWPH From the Last 2 Days
There are no results for your query GWPH